CABA net incomeQ3 2026-$53.05M
CABA net income was -$53.05M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$44.87M a year earlier. For the full fiscal 2025 it was -$167.86M, compared with -$115.86M in fiscal 2024.
Cabaletta Bio Inc. (CABA) financials
For the twelve months ended Sep 30, 2026, Cabaletta Bio Inc. reported -$189.50M of net income.
- Net income, TTM
- -$189.50M
- Free cash flow, TTM
- -$162.51M
- Cash
- $299.38M
- Market cap
- $221.3M
FY2018FY2025
FY2019FY2025
CABA revenue and earnings growth
CABA EPSQ3 2026-$0.28
CABA diluted EPS was -$0.28 in fiscal Q3 2026 (ended Sep 30, 2026). For the full fiscal 2025 it was -$2.10.
CABA free cash flowQ3 2026-$42.89M
CABA free cash flow was -$42.89M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$34.59M a year earlier. For the full fiscal 2025 it was -$132.31M, compared with -$90.43M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
|---|---|---|---|---|---|---|---|---|
| Research and development | $142.67M | $97.20M | $55.42M | $39.30M | $32.49M | $21.38M | $11.67M | $4.47M |
| Selling, general and admin | $29.57M | $27.94M | $19.24M | $14.84M | $13.82M | $12.46M | $7.01M | $1.73M |
| Operating income | -$172.24M | -$125.14M | -$74.66M | -$54.14M | -$46.31M | -$33.83M | -$18.68M | -$6.19M |
| Interest expense | $2.00M | $748.0K | $0 | - | - | - | - | - |
| Income tax | $0 | $0 | - | - | - | - | - | - |
| Net income | -$167.86M | -$115.86M | -$67.67M | -$52.98M | -$46.29M | -$33.34M | -$16.94M | -$12.20M |
| EPS, basic | -$2.10 | -$2.34 | -$1.65 | -$1.81 | -$1.80 | -$1.44 | -$4.07 | -$6.87 |
| EPS, diluted | -$2.10 | -$2.34 | -$1.65 | -$1.81 | -$1.80 | -$1.44 | -$4.07 | -$6.87 |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $82.98M | $163.96M | $193.24M | $81.61M | $122.22M | $101.43M | $136.20M | $33.02M |
| Short-term investments | $50.62M | $0 | $48.01M | $24.94M | $0 | $7.23M | - | - |
| Current assets | $138.87M | $166.68M | $244.49M | $108.83M | $124.54M | $113.53M | $140.55M | $33.99M |
| Total assets | $165.08M | $185.05M | $253.65M | $116.97M | $126.34M | $114.72M | $141.47M | $34.17M |
| Current liabilities | $50.15M | $27.09M | $15.99M | $9.49M | $8.38M | $5.18M | $3.15M | $943.0K |
| Total liabilities | $53.03M | $32.71M | $17.45M | $12.45M | $8.38M | - | - | - |
| Shareholders' equity | $112.05M | $152.34M | $236.20M | $104.52M | $117.96M | $109.54M | $138.32M | -$10.69M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$131.08M | -$88.22M | -$53.55M | -$46.38M | -$34.11M | -$26.77M | -$16.05M | -$4.66M |
| Capital expenditures | $1.23M | $2.21M | $687.0K | $2.45M | $1.17M | $635.0K | $693.0K | - |
| Free cash flow | -$132.31M | -$90.43M | -$54.24M | -$48.83M | -$35.27M | -$27.41M | -$16.74M | - |
| Investing cash flow | -$50.27M | $47.29M | -$22.45M | -$27.22M | $6.00M | -$7.98M | -$693.0K | - |
| Financing cash flow | $100.35M | $11.68M | $187.63M | $32.98M | $48.90M | -$24.0K | $119.92M | $37.68M |
| Stock-based compensation | $20.94M | $19.46M | $11.34M | $6.90M | $5.80M | $4.39M | $2.30M | $606.0K |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
|---|---|---|---|---|---|---|---|---|
| Return on equity | -149.8% | -76.1% | -28.7% | -50.7% | -39.2% | -30.4% | -12.2% | - |
| Return on assets | -101.7% | -62.6% | -26.7% | -45.3% | -36.6% | -29.1% | -12.0% | -35.7% |
| Current ratio | 2.77 | 6.15 | 15.29 | 11.47 | 14.86 | 21.92 | 44.66 | 36.05 |
Income statement
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $47.14M | $44.43M | $37.35M | $36.19M | $39.82M | $37.64M | $29.02M | $25.53M | $26.29M | $23.43M | $21.95M | $17.41M |
| Selling, general and admin | $7.56M | $7.59M | $6.94M | $6.42M | $6.76M | $8.27M | $8.12M | $8.25M | $6.76M | $6.85M | $6.08M | $5.74M |
| Operating income | -$54.71M | -$52.02M | -$44.30M | -$42.61M | -$46.59M | -$45.91M | -$37.14M | -$33.78M | -$33.05M | -$30.28M | -$28.03M | -$23.15M |
| Interest expense | $511.0K | $517.0K | $636.0K | $555.0K | $584.0K | $571.0K | $294.0K | $748.0K | $0 | $0 | $0 | - |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | - |
| Net income | -$53.05M | -$51.02M | -$43.52M | -$41.92M | -$44.87M | -$45.13M | -$35.94M | -$32.59M | -$30.63M | -$27.60M | -$25.05M | -$20.89M |
| EPS, basic | -$0.28 | -$0.34 | -$0.39 | - | -$0.44 | -$0.73 | -$0.71 | - | -$0.62 | -$0.56 | -$0.51 | - |
| EPS, diluted | -$0.28 | -$0.34 | -$0.39 | - | -$0.44 | -$0.73 | -$0.71 | - | -$0.62 | -$0.56 | -$0.51 | - |
| Diluted shares | 186.8M | 151.2M | 112.0M | - | 102.3M | 61.9M | 50.7M | - | - | - | - | - |
Balance sheet
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $299.38M | $225.10M | $116.64M | $82.98M | $60.21M | $145.61M | $131.83M | $163.96M | $170.61M | $178.61M | $175.29M | $193.24M |
| Short-term investments | $0 | $0 | $0 | $50.62M | $99.72M | $49.07M | - | $0 | $12.40M | $24.61M | $48.55M | $48.01M |
| Current assets | $309.85M | $231.03M | $122.32M | $138.87M | $164.56M | $198.41M | $134.60M | $166.68M | $185.51M | $206.26M | $227.48M | $244.49M |
| Total assets | $336.49M | $256.73M | $148.15M | $165.08M | $189.76M | $224.50M | $165.14M | $185.05M | $204.41M | $217.42M | $240.46M | $253.65M |
| Current liabilities | $47.33M | $39.91M | $41.51M | $50.15M | $45.73M | $41.54M | $33.99M | $27.09M | $22.88M | $17.90M | $17.97M | $15.99M |
| Total liabilities | $52.57M | $46.13M | $44.84M | $53.03M | $50.29M | $46.02M | $43.59M | $32.71M | $30.17M | $17.90M | $18.74M | $17.45M |
| Shareholders' equity | $283.92M | $210.59M | $103.31M | $112.05M | $139.47M | $178.48M | $121.55M | $152.34M | $174.24M | $199.52M | $221.72M | $236.20M |
Cash flow
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$42.74M | -$41.51M | -$42.56M | -$35.34M | -$34.51M | -$30.43M | -$30.80M | -$23.12M | -$20.32M | -$20.79M | -$23.99M | -$16.45M |
| Capital expenditures | $142.0K | $0 | $0 | $205.0K | $78.0K | $161.0K | $785.0K | $376.0K | $253.0K | $770.0K | $812.0K | $185.0K |
| Free cash flow | -$42.89M | -$41.51M | -$42.56M | -$35.55M | -$34.59M | -$30.59M | -$31.59M | -$23.50M | -$20.58M | -$21.56M | -$24.80M | -$16.63M |
| Investing cash flow | -$142.0K | $0 | $50.96M | $49.80M | -$50.08M | -$49.20M | -$785.0K | $12.12M | $12.25M | $23.73M | -$812.0K | $1.14M |
| Financing cash flow | $117.19M | $149.99M | $25.27M | $8.33M | -$806.0K | $93.37M | -$552.0K | $4.37M | $71.0K | $379.0K | $6.86M | $93.05M |
| Stock-based compensation | $5.26M | $5.50M | $5.26M | $4.26M | $5.82M | $5.71M | $5.16M | $5.41M | $5.25M | $5.01M | $3.79M | $3.05M |
Key ratios
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 6.55 | 5.79 | 2.95 | 2.77 | 3.60 | 4.78 | 3.96 | 6.15 | 8.11 | 11.52 | 12.66 | 15.29 |
Source: XBRL data Cabaletta Bio Inc. files with the SEC, latest filing dated Nov 5, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
CABA peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| CABA | - | - | -$189.50M | - | $221.3M |
| AMGN | $38.90B | +8.2% | $9.39B | 24.1% | $249.05B |
| GILD | $30.99B | +6.5% | -$3.86B | -12.5% | $207.00B |
| MRNA | $2.52B | +13.1% | -$2.79B | -110.5% | $101.48B |
| ARGX | $4.25B | +88.6% | $1.29B | 30.4% | $57.55B |
| RVMD | $0 | - | -$1.13B | - | $41.59B |
| BIIB | $10.30B | +2.3% | $347.50M | 3.4% | $36.71B |
| BNTX | €2.87B | +4.3% | -€1.14B | -39.6% | $21.98B |
| EXEL | $2.50B | +9.1% | $885.14M | 35.5% | $16.98B |
CABA FAQ
5 questionsIs CABA profitable?
No. Cabaletta Bio Inc. reported a net loss of $189.50M for the twelve months ended Sep 30, 2026.How much cash and debt does CABA have?
Cabaletta Bio Inc. reported $299.38M in cash and cash equivalents on its most recent balance sheet in SEC filings.What is CABA free cash flow?
Cabaletta Bio Inc. generated -$162.51M of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of -$162.16M less capital expenditures.When did CABA last report financial results?
The latest statements here come from Cabaletta Bio Inc.'s 10-Q filed on Nov 5, 2026, covering the period ended Sep 30, 2026.Where does this CABA financial data come from?
Quantisnow builds these statements from the structured XBRL data Cabaletta Bio Inc. files with the SEC. It is provided for information only and is not investment advice.